Cellectar Biosciences, INC 10-Q quarterly reports

Cellectar Biosciences reported increased R&D spending and positive clinical trial data for iopofosine I 131, but faces substantial doubt regarding its ability to continue as a going concern.

Cellectar Biosciences reports Q1 2026 results with reduced R&D expenses, increased manufacturing costs, and a significant financing round, while advancing its iopofosine I 131 program.

Cellectar Biosciences reported significantly reduced net losses and R&D expenses for the nine months ended September 30, 2025, while advancing its lead drug candidate, iopofosine I 131, with FDA Breakthrough Therapy Designation and positive EMA guidance for Waldenstrom macroglobulinemia.

Cellectar Biosciences reported a reduced net loss in Q2 2025, driven by lower R&D and G&A expenses, while announcing a strategic review and Breakthrough Therapy Designation for iopofosine I 131, but faces significant going concern doubts due to limited cash.

Cellectar Biosciences reports Q1 2025 results with a net loss of $6.6 million and explores strategic alternatives amid going concern uncertainties, despite positive clinical data from its CLOVER-WaM study.

Cellectar Biosciences announced its third quarter 2024 financial results, highlighting clinical trial progress and a restatement of prior financial statements due to accounting errors.

Cellectar Biosciences' second quarter 2024 results show increased research and development spending, a net loss, and a strengthened cash position due to warrant exercises.

Cellectar Biosciences has restated its prior financial statements due to errors in accounting for warrants and preferred stock, while also reporting a net loss of $26.6 million for the first quarter of 2024.

Cellectar Biosciences announced positive topline results from its pivotal CLOVER-WaM trial and provided a financial update for the first quarter of 2024, highlighting increased cash reserves and ongoing research and development efforts.